Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | IMpower133: atezolizumab, carboplatin plus etoposide for SCLC

Martin Reck • 30 Sep 2019
ESMO 2019
Lung Cancer Small Cell Lung Cancer Atezolizumab Carboplatin Etoposide
IMpower133

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses the IMpower133 (NCT02763579) trial updated overall survival (OS) analysis of first-line atezolizumab plus carboplatin plus etoposide in extensive-stage small-cell lung cancer SCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Martin Reck

5:41
JAVELIN Lung100, PRIMUS, NintNivo, IMpower010: investigating IO in NSCLC
Martin Reck • 8 Aug 2022
2:35
Atezo maintenance therapy improves survival in the IMpower133 trial of ES-SCLC
Martin Reck • 1 Feb 2021
3:03
KEYNOTE-799: pembro + chemoradiotherapy in locally advanced NSCLC
Martin Reck • 1 Feb 2021
3:24
Pembro +/- ipi in metastatic NSCLC: KEYNOTE-598
Martin Reck • 1 Feb 2021

Related Videos

0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals